Comparison of ultrasound-guided subacromial corticosteroid and ozone (O2-O3) injections in the treatment of chronic rotator cuff tendinopathy: a randomized clinical trial

The requested reference [87702c0c442157f91752a2d2aea18f51de4da4aa] no longer exists in our database. It has been replaced by the current reference: [9e495dab46c7013708c88b2723ea1098ed48fb74]

Authors
Category Primary study
JournalKOREAN JOURNAL OF PAIN
Year 2023
Background: The authors aimed to compare the effects of a one-time ultrasound (US)-guided subacromial corticosteroid injection and three-time ozone (O2-O3) injection in patients with chronic supraspinatus tendinopathy.Methods: Participants were randomly assigned to the corticosteroid group (n = 22) or ozone group (n = 22). Injections in both groups were administered into subacromial bursa with an US-guided in-plane posterolateral approach. Primary outcome measure was the change in the Western Ontario Rotator Cuff Index (WORC) score between baseline and 12-weeks post-injection. Secondary outcome measures included visual analog scale and Shoulder Pain and Disability Index scores. Assessments were recorded at baseline, and 4-weeks and 12-weeks post-injection.Results: Forty participants completed this study. Based on repeated measurement analysis of variance, a significant effect of time was found for all outcome measures in both groups. Both the groups showed clinically significant improvements in shoulder pain, quality of life, and function. Baseline, 4-week post-injection, and 12-week post-injection WORC scores (mean +/- standard deviation) were 57.91 +/- 18.97, 39.10 +/- 20.50 and 37.22 +/- 27.31 in the corticosteroid group, respectively and 69.03 +/- 15.89, 39.11 +/- 24.36, and 32.26 +/- 24.58 in the ozone group, respectively. However, no significant group x time interaction was identified regarding all outcome measures.Conclusions: Three-time ozone injection was not superior to a one-time corticosteroid injection in patients with chronic supraspinatus tendinopathy. It might be as effective as corticosteroid injection at 4-weeks and 12-weeks post-injection in terms of relieving pain and improving quality of life and function.
Epistemonikos ID: 9e6da596359dbcb973e73f8822546c292dd0520e
First added on: Jul 06, 2023